These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38900051)

  • 21. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy.
    Guo S; Lei W; Jin X; Liu H; Wang JQ; Deng W; Qian W
    Blood Adv; 2024 Jun; 8(11):2635-2645. PubMed ID: 38564778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7.
    Poorebrahim M; Quiros-Fernandez I; Marmé F; Burdach SE; Cid-Arregui A
    Cancer Lett; 2023 Jul; 566():216242. PubMed ID: 37217069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
    Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
    Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
    [No Abstract]   [Full Text] [Related]  

  • 24. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.
    Sun C; Shou P; Du H; Hirabayashi K; Chen Y; Herring LE; Ahn S; Xu Y; Suzuki K; Li G; Tsahouridis O; Su L; Savoldo B; Dotti G
    Cancer Cell; 2020 Feb; 37(2):216-225.e6. PubMed ID: 32004441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD81 costimulation skews CAR transduction toward naive T cells.
    Schultz LM; Czerwinski DK; Levy R; Levy S
    Proc Natl Acad Sci U S A; 2022 Feb; 119(5):. PubMed ID: 35091467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
    Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
    Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
    [No Abstract]   [Full Text] [Related]  

  • 27. CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance.
    Wu L; Brzostek J; Sakthi Vale PD; Wei Q; Koh CKT; Ong JXH; Wu LZ; Tan JC; Chua YL; Yap J; Song Y; Tan VJY; Tan TYY; Lai J; MacAry PA; Gascoigne NRJ
    Cell Rep Med; 2023 Feb; 4(2):100917. PubMed ID: 36696897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integration of ζ-deficient CARs into the CD3ζ gene conveys potent cytotoxicity in T and NK cells.
    Kath J; Franke C; Drosdek V; Du W; Glaser V; Fuster-Garcia C; Stein M; Zittel T; Schulenberg S; Porter CE; Andersch L; Künkele A; Alcaniz J; Hoffmann J; Abken H; Abou-El-Enein M; Pruß A; Suzuki M; Cathomen T; Stripecke R; Volk HD; Reinke P; Schmueck-Henneresse M; Wagner DL
    Blood; 2024 Jun; 143(25):2599-2611. PubMed ID: 38493479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7.
    Amatya C; Pegues MA; Lam N; Vanasse D; Geldres C; Choi S; Hewitt SM; Feldman SA; Kochenderfer JN
    Mol Ther; 2021 Feb; 29(2):702-717. PubMed ID: 33129371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3ζ -engineered NK cells mediates antitumor effects.
    Li S; Zhang C; Shen L; Teng X; Xiao Y; Yu B; Lu Z
    Cancer Immunol Immunother; 2023 Mar; 72(3):769-774. PubMed ID: 35988132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy.
    Hajari Taheri F; Hassani M; Sharifzadeh Z; Behdani M; Arashkia A; Abolhassani M
    IUBMB Life; 2019 Sep; 71(9):1259-1267. PubMed ID: 30724452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions.
    Meng X; Jing R; Qian L; Zhou C; Sun J
    Front Immunol; 2020; 11():1046. PubMed ID: 32636832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of CD28-mediated natural cytotoxicity by KIR2DL2 does not require p56(lck) in the NK cell line YT-Indy.
    Tarazona R; Borrego F; Galiani MD; Aguado E; Peña J; Coligan JE; Solana R
    Mol Immunol; 2002 Jan; 38(7):495-503. PubMed ID: 11750651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 38. High specificity of engineered T cells with third generation CAR (CD28-4-1BB-CD3-ζ) based on biotin-bound monomeric streptavidin for potential tumor immunotherapy.
    Gallego-Valle J; Pérez-Fernández VA; Rosales-Magallares J; Gil-Manso S; Castellá M; Gonzalez-Navarro EA; Correa-Rocha R; Juan M; Pion M
    Front Immunol; 2024; 15():1448752. PubMed ID: 39364400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excessive Costimulation Leads to Dysfunction of Adoptively Transferred T Cells.
    Wijewarnasuriya D; Bebernitz C; Lopez AV; Rafiq S; Brentjens RJ
    Cancer Immunol Res; 2020 Jun; 8(6):732-742. PubMed ID: 32213625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 4-1BB enhancement of CAR T function requires NF-κB and TRAFs.
    Li G; Boucher JC; Kotani H; Park K; Zhang Y; Shrestha B; Wang X; Guan L; Beatty N; Abate-Daga D; Davila ML
    JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.